Meeting
2022 ASCO Annual Meeting
Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.
Authors
Xiuxiu Yang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xiuxiu Yang , Peiling Zhang , Yang Cao , Jue Wang , Mi Zhou , Chunrui Li , Jianfeng Zhou , Liang Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
ChiCTR2100053662
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7532)
DOI
10.1200/JCO.2022.40.16_suppl.7532
Abstract #
7532
Poster Bd #
186
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
First Author: Laura S. Samples
Poster
2017 ASCO Annual Meeting
Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL.
First Author: Jae Hong Park
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson